Drugmaker Rovi's net profit rises on higher Okedi, heparin sales
25/02/2026 09:19
Feb 25 (Reuters) - Spanish drugmaker Laboratorios Farmaceuticos Rovi ROVI.MC said on Wednesday its 2025 net profit rose 3% as higher sales of its schizophrenia drug Okedi and heparin products - as well as recognition of R&D aid - offset a decline in contract manufacturing revenue. Full-year net profit rose to 140.4 million euros, while operating revenue fell 3% to 743.5 million euros CDMO revenue dropped 20% to 269.5 million euros on negligible Moderna-related revenue and lower production volumes for Moderna Specialty pharmaceutical revenue increased 11% to 473.9 million euros, driven by a 97% rise in Okedi sales and 7% in the heparin franchise, which includes low molecular weight heparins (LMWH) and other heparins Gross profit rose 3% to 494.7 million euros, supported by 36.3 million euros in R&D aid and lower LMWH raw material prices Rovi will propose a dividend of 0.96 euros per share, a payout of around 35% It expects 2026 operating revenue to grow by a high single-digit to low double-digit percentage (Reporting by Marta Serafinko in Gdansk; Editing by David Latona) ((Marta.Serafinko@thomsonreuters.com; +48 58 769 66 00;))